Ipilimumab/nivolumabGrade-3 enterocolitis : case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2024年 / 2018卷 / 1期

关键词：

D O I：

10.1007/s40278-024-63712-y

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：253 / 253

相关论文

共 50 条

[1] Ipilimumab/nivolumabGrade 3 colitis: case report
[J]. Reactions Weekly, 2023, 1986 (1) : 222 - 222
[2] Ipilimumab/nivolumabGrade 3 autoimmune hepatitis: case report
[J]. Reactions Weekly, 2022, 1929 (1) : 359 - 359
[3] Ipilimumab/nivolumabImmunomodulatory enterocolitis: case report
[J]. Reactions Weekly, 2018, 1710 (1) : 179 - 179
[4] Ipilimumab/nivolumabSevere enterocolitis: case report
[J]. Reactions Weekly, 2021, 1865 (1) : 240 - 240
[5] NivolumabGrade 3 diarrhoea: case report
[J]. Reactions Weekly, 2017, 1658 (1) : 350 - 350
[6] NivolumabGrade 3 diarrhoea: case report
[J]. Reactions Weekly, 2022, 1900 (1) : 256 - 256
[7] Ipilimumab/nivolumabLack of efficacy and enterocolitis: case report
[J]. Reactions Weekly, 2020, 1817 (1) : 182 - 182
[8] Durvalumab/ipilimumab/nivolumabGrade 5 pneumonitis: 2 case reports
[J]. Reactions Weekly, 2021, 1871 (1) : 155 - 155
[9] Ipilimumab/nivolumabImmune- related thyroiditis and enterocolitis: case report
[J]. Reactions Weekly, 2021, 1859 (1) : 198 - 198
[10] Ipilimumab/nivolumabGrade 5 gastrointestinal complications
[J]. Reactions Weekly, 2024, 2008 (1) : 182 - 182

← 1 2 3 4 5 →